| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000006557 |
| Receipt No. | R000007770 |
| Official scientific title of the study | Evaluating biomarkers for idiopathic interstitial pneumonia. |
| Date of disclosure of the study information | 2011/10/20 |
| Last modified on | 2016/04/17 (Ver. 4) |
| Basic information | ||
| Official scientific title of the study | Evaluating biomarkers for idiopathic interstitial pneumonia. | |
| Title of the study (Brief title) | New biomarkers for idiopathic interstitial pneumonia. | |
| Region |
|
|
| Condition | ||
| Condition | interstitial pneumonia | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | Evaluating lipid mediators and their producing enzymes in serum and BAL fluid from patients with interstitial pneumonia. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Changes in concentration according to disease progress. |
| Key secondary outcomes | |
| In outcomes field, the entry of just a few words such as "safety" or "efficiency" will not be accepted. Specify the name of outcome measures, including the time when you plan to measure. Usually, only one primary outcome is accepted. Write the other outcomes in "secondary outcomes" field. |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| In interventions field, include the details of interventions, such as duration, amount, and frequency. If the intervention includes prescription or use of medical devices, duration is required. |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Patients who are diagnosed as interstitial pneumonia. | |||
| Key exclusion criteria | Patients who disagree with involving in this study. | |||
| Target sample size | 100 | |||
| Research contact person | |
| Name of lead principal investigator | Hiroshi KUBO |
| Organization | Tohoku University Graduate School of Medicine |
| Division name | Department of Advanced Preventive Medicine for Infectious Disease |
| Address | 2-1 Seiryoumachi, Aobaku Sendai JAPAN |
| TEL | 022-717-7174 |
| hkubo@med.tohoku.ac.jp | |
| Public contact | |
| Name of contact person | Hiroshi KUBO |
| Organization | Tohoku University Graduate School of Medicine |
| Division name | Department of Advanced Preventive Medicine for Infectious Disease |
| Address | 2-1 Seiryoumachi, Aobaku Sendai JAPAN |
| TEL | 022-717-7184 |
| Homepage URL | |
| hkubo@med.tohoku.ac.jp | |
| Sponsor | |
| Institute | Department of Advanced Preventive Medicine for Infectious Disease, Tohoku University Graduate School of Medicine |
| Institute | |
| Department | |
| Sponsor means an organization that is responsible for plan, deployment and report of the research including funding management. It doesn't mean funding agency". Therefore, all clinical trial should have the one. |
| Funding Source | |
| Organization | National Institute of Biomedical Innovation |
| Organization | |
| Division | |
| Category of Funding Organization | Non profit foundation |
| Nationality of Funding Organization | Japan |
| Other related organizations | |
| Co-sponsor | Japanese Red-Cross Ishinomaki Hospital |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | Sampling is made only from patients who are diagnosed as interstitial pneumonia. |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000007770 |